NOMINATING COMMITTEE APPOINTED IN KARO BIO AB
STOCKHOLM, March 15, 2013 - Karo Bio AB (publ). As changes in ownership structure could be expected upon completion of the right issue last year, the Board has considered it prudent to await the outcome before a Nomination Committee was appointed.
In accordance with the principles adopted by the AGM for appointing the Nomination Committee, the following persons have been appointed, together the Chairman of the Board, to constitute the Nomination Committee for the period up to the 2013 AGM:
- Lars Magnusson
- Per-Anders Johansson
- Thomas Andersson
- Jan Lundström
Proposals from shareholders should be submitted to the following address: Nominating Committee, Karo Bio AB, Novum, 141 57 Huddinge, Sweden. The Nominating Committee’s mandate period runs until the appointment of a new committee by the shareholders at the 2013 AGM.
For further information, please contact:
Per Bengtsson, CEO, mobile +46 734 474 128 or e-mail firstname.lastname@example.org
Henrik Palm, CFO, mobile +46 70 540 4014 or e-mail email@example.com
About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas neuropsychiatry, inflammation, autoimmune diseases and cancer. An important foundation for the company’s activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 43 employees and is listed on NASDAQ OMX Stockholm.
Karo Bio publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication on March 15, 2013, at 11:15 am CET.
This press release is also available at www.karobio.com and www.newsroom.cision.com